Coverage
-
April 30, 2015
A class of ViroPharma Inc. shareholders claiming the company intentionally misled investors regarding market exclusivity for its signature gastrointestinal antibiotic asked a Pennsylvania federal judge Wednesday to approve an $8 million settlement reached through mediation, saying continued litigation could reduce or eliminate future recovery.
2 other articles on this case.
View all »